Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis-Reference-Cited by-同舟云学术

Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis

Published:2007-03-31 Issue:3 Volume:5 Page:291-300
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

NORLANDER B.,GOTTHARD R.,STRÖM M.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.1991.tb00030.x/fullpdf

Reference8 articles.

1. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease;Jarnerot;Drugs,1989

2. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet;Hardy;Aliment Pharmacol Therap,1987

3. Pharmacokinetics of a 5-amino-salicylic acid enteric-coated tablet and suppository dosage form;Norlander;Aliment Pharmacol Therap,1989

4. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers;Norlander;Aliment Pharmacol Therap,1990

5. Rederived Values of the Eight Coefficients of the Crohn's Disease Activity Index (CDAI);Best;Gastroenterology,1979

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2018-05-17

2. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers;Alimentary Pharmacology & Therapeutics;2007-03-31

3. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters;Alimentary Pharmacology & Therapeutics;2001-01-17

4. Upper and Lower Limits in the Renal Clearance of Acetylmesalazine in Humans;Clinical Drug Investigation;2001

5. Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease;Clinical Pharmacokinetics;2001